AIM
BPMC

Acrospire Investment Management’s Blueprint Medicines BPMC Stock Holding History

Acrospire Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-648
Closed -$26K – 2182
2017
Q1 		$26K Sell
648
-1,100
-63% -$39.4K 0.02% 1450
2016
Q4 		$49K Sell
1,748
-1,500
-46% -$45.2K 0.02% 1406
2016
Q3 		$96K Buy
3,248
+700
+27% +$17.4K 0.06% 589
2016
Q2 		$52K Buy
+2,548
New +$46.3K 0.04% 1029

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acrospire Investment Management's BPMC Position: Q2 2017 in Review

Acrospire Investment Management sold out of Blueprint Medicines (BPMC) in Q2 2017, closing a stake of 648 shares — an estimated $26K sold.

Acrospire Investment Management first reported a position in BPMC in Q2 2016 and held it in 4 quarters. The position peaked at $96K in Q3 2016. 124 funds tracked by Wall St. Rank hold BPMC as of Q2 2017.

  • Acrospire Investment Management reported no remaining Blueprint Medicines position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 648 Blueprint Medicines shares in Q2 2017, an estimated $26K.
  • Acrospire Investment Management first reported a position in Blueprint Medicines in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Blueprint Medicines position peaked at $96K in Q3 2016.
  • 124 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.